Agenda-8-27-21

The Live Virtual Experience will include top experts sharing highlights from over 25 on-demand presentations*, available 9 September 2021. The on-demand presentations will be available through the virtual platform. These interactive panel discussions will also feature debates and Q&A from the live audience.

= On-Demand Presentation
 
= Live Presentation
 
** = Oral Presenation

Friday 17 September 2021

Day 1
9:00 AM (EDT)
15:00 (CEST)
5 mins Opening Remarks
Tadeusz Robak, MD, PhD
    Theme 1: Pathogenesis of CLL  
9:05 AM (EDT)
15:05 (CEST)
5 mins Session 1: Molecular Pathogenesis of CLL – Genomics and Proteomics

Co-Chairs: Catherine J. Wu, MD
& Clare Sun, MD
    Genomic Analysis of CLL
On-Demand Presentation

Anna Schuh, MD, PhD
    Novel Insights From Proteogenomic Analysis
On-Demand Presentation
Michael Gillette, MD, PhD
9:10 AM (EDT)
15:10 (CEST)
30 mins Panel Discussion featuring highlights from the following on-demand presentations:
*Genomic Analysis of CLL &
*Novel Insights From Proteogenomic Analysis
Catherine J. Wu, MD; Clare Sun, MD; Anna Schuh, MD, PhD; Michael Gillette, MD, PhD
9:40 AM (EDT)
15:40 (CEST)
10 mins **Effects of SF3B1 K700E mutation in chronic lymphocytic leukemia
and the opportunity for targeted therapy with SF3B1-binding splicing
modulator H3B-8800
(1084295)
Irene Lopez-Oreja, PhD
9:50 AM (EDT)
15:50 (CEST)
10 mins **Patterns of BTK Mutation and Clonal Evolution Induced by the Selective BTK Inhibitor (BTKi), Tirabrutinib in Chronic Lymphocytic
Leukaemia (CLL)
(1083945)
Ross Jackson, PhD
10:00 AM (EDT)
16:00 (CEST)
5 mins Visit Exhibit Hall & Break  
10:05 AM (EDT)
16:05 (CEST)
5 mins Session 2: Molecular Pathogenesis of CLL – Microenvironment
& Signaling

Co-Chairs: Nicholas Chiorazzi, MD
& Sarka Pospisilova, PhD
   

Trafficking of CLL Cells To and From the Microenvironmental Niche
On-Demand Presentation

 

Andrea Pepper, PhD
    Effects of Distinct Receptor-Ligand Systems (BCR, TLR, Chemokine Receptors) in the Survival and Growth of CLL Cells
On-Demand Presentation

Dimitar Efremov, MD, PhD
    Crosstalk of Microenvironmental Elements in the Tissue Microenvironment
On-Demand Presentation

Alan Ramsay, PhD
10:10 AM (EDT)
16:10 (CEST)
36 mins Panel Discussion featuring highlights from the following
on-demand presentations:
*Trafficking of CLL Cells To and From the Microenvironmental Niche
*Effects of Distinct Receptor-Ligand Systems (BCR, TLR, Chemokine Receptors) in the Survival and Growth of CLL Cells
*Crosstalk of Microenvironment Elements in the
Tissue Microenvironment
Nicholas Chiorazzi, MD; Sarka Pospisilova, PhD; Andrea  Pepper, PhD; Dimitar Efremov, MD, PhD; Alan Ramsay, PhD
10:46 AM (EDT)
16:46 (CEST)
7 mins **Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated by Epigenetic Plasticity of Residual Disease and By-pass Signaling via
MAPK Pathway
(1084084)
Lodovico Terzi di Bergamo, MSc
10:53 AM (EDT)
16:53 (CEST)
7 mins **GAB1 – Novel Regulator of Migration Capacity and Tonic AKT Activity in CLL: Implications for Combinatorial Therapy with BCR Inhibitors
(1084081)
Vaclav Seda, MSc
11:00 AM (EDT)
17:00 (CEST)
5 mins Visit Exhibit Hall & Break  
11:05 AM (EDT)
17:05 (CEST)
5 mins Session 3: Clonal Dynamics, Competition, and Disease Evolution
Co-Chairs: Gianluca Gaidano, MD, PhD
& Adalgisa Condoluci, MD
    Mechanisms of Epigenetic Dynamics/Evolution
On-Demand Presentation

Davide Rossi, MD, PhD
    Perspectives of Clonal Evolution at the Single-Cell Level
On-Demand Presentation

Catherine J. Wu, MD
11:10 AM (EDT)
17:10 (CEST)
10 mins **Single-cell Dynamics of Mitochondrial DNA Mutations and Chromatin Accessibility in Chronic Lymphocytic Leukemia Following Therapeutic Bottlenecks
(1084075)
Livius Penter, MD
11:20 AM (EDT)
17:20 (CEST)
10 mins **Venetoclax resistance mechanisms in CLL identified by whole exome
and RNA sequencing on longitudinal patient samples
(1084402)
Jasneet K. Khalsa, PhD
11:30 AM (EDT)
17:30 (CEST)
30 mins Panel Discussion featuring highlights from the following on-demand presentations:
*Mechanisms of Epigenetic Dynamics/Evolution
*Perspectives of Clonal Evolution at the Single-Cell Level
Gianluca Gaidano, MD, PhD; Adalgisa Condoluci, MD; Davide Rossi, MD, PhD; Catherine J. Wu, MD
12:00 PM (EDT)
18:00 (CEST)
  End of Day 1  
12:00 PM (EDT)
18:00 (CEST)
60 mins Poster Session

 
12:00 PM (EDT)
18:00 (CEST)
  Establishment and Molecular Characterization of a 3D Bioprinted
Chronic Lymphocytic Leukemia (CLL) in Vitro Model
(1083882)
Riccardo Pinos, MSc
12:05 PM (EDT)
18:05 (CEST)
  Ibrutinib Blocks CD40 Signaling in CLL in Vivo by Reducing TRAF4 Levels
(1084082)
Sonali Sharma, PhD
12:10 PM (EDT)
18:10 (CEST)
  Role of Ahr and Hif1a in the Suppressive Ability of Tregs During CLL Development
(1083804)
Giulia Maria Pagano, MSc
12:15 PM (EDT)
18:15 (CEST)
  Single-cell RNA Sequencing Suggests Novel Drivers of Chronic Lymphocytic Leukemia in Patients with Ibrutinib Resistance
(1084066)
Hui Jin, MD
12:20 PM (EDT)
18:20 (CEST)
  Analysis of BTK-independent Calcium Signaling Downstream of
the B-cell Receptor Signaling in Human Malignant B Cells
(1083841)
Beatriz Valle-Argos, PhD
12:25 PM (EDT)
18:25 (CEST)
  Detection of Rare Germline Variants in the Genomes of Patients
with B-Cell Neoplasms
(1084074)
Adrián Mosquera Orgueira, MD
12:30 PM (EDT)
18:30 (CEST)
  GEUS-CLL: a comprehensive assay that integrates (epi)genetic information with clinical impact in CLL
(1084248)
Ester Cuenca-Leon, PhD
12:35 PM (EDT)
18:35 (CEST)
  IL4-STAT6 Signaling Induces CD20 in Chronic Lymphocytic Leukemia and This Axis Is Repressed by PI3Kδ Inhibitor Idelalisib
(1084080)
Marek Mraz, MD, PhD
12:40 PM (EDT)
18:40 (CEST)
  Discussion  
1:00 PM (EDT)
19:00 (CEST)
  Poster Session Concludes  

Saturday 18 September 2021

Day 2
    Theme 2: Approach Considerations and Treatment Options in CLL  
9:00 AM (EDT)
15:00 (CEST)
5 mins Opening Remarks & Recap of Previous Day

Kostas Stamatopoulos, MD, PhD

9:05 AM (EDT)
15:05 (CEST)
5 mins Session 4: Prognostication and Prediction in the Era of Novel Drugs

Chair: Peter Hillmen, MB ChB, PhD & Carol Moreno, MD, PhD
    The Use of Conventional Prognostic Markers with Targeted Therapy
On-Demand Presentation

Eugen Tausch, MD
    Genomic Profiling and Treatment Decisions in the Non-Chemotherapy Era
On-Demand Presentation

Romain Guièze, MD
9:10 AM (EDT)
15:10 (CEST)
45 mins Panel Discussion featuring highlights from the following on-demand presentations:
*The Use of Conventional Prognostic Markers with Targeted Therapy
*Genomic Profiling and Treatment Decisions in the Non-Chemotherapy Era
Peter Hillmen, MB ChB, PhD; Eugen Tausch, MD; Romain Guièze, MD; Carol Moreno, MD, PhD
9:55 AM (EDT)
15:55 (CEST)
10 mins **Integration of pre-, on- and post-treatment risk factors, including CLL-IPI and MRD, improves outcome prediction after fixed-duration therapy of CLL: Introduction of the refined Continuous Individualized Risk Index (CIRI2-CLL)
(1084256)
Othman Al-Sawaf, MD
10:05 AM (EDT)
16:05 (CEST)
10 mins **The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Disease-specific Comorbidity Scale Validated in Two Independent Cohorts
(1083230)
Max J. Gordon, MD
10:15AM (EDT)
16:15 (CEST)
5 mins Visit Exhibit Hall & Break  
10:20 AM (EDT)
16:20 (CEST)
5 mins Session 5: Minimal Residual Disease – Methods and Clinical Application

Co-Chairs: Thomas Kipps, MD, PhD
& Kirsten Fischer, MD
    Minimal Residual Disease
On-Demand Presentation

William Wierda, MD, PhD
10:25 AM (EDT)
16:25 (CEST)
20 mins Debate: To MRD or Not to MRD – Can We Use MRD to
Direct Standard Practice?

Moderator:  Thomas Kipps, MD, PhD

Debaters:
Peter Hillmen,MB, ChB, PhD;
John Burke, MD

10:45 AM (EDT)
16:45 (CEST)
25 mins Panel Discussion featuring highlights from the following on-demand presentations:
*Minimal Residual Disease
Thomas Kipps, MD, PhD; Kirsten Fischer, MD; William Wierda, MD, PhD
11:10 AM (EDT)
17:10 (CEST)
10 mins **Cell-free DNA (cfDNA)-based Serial Minimal Residual Disease Assessment in Patients with Chronic Lymphocytic Leukemia Treated with Time-limited Obinutuzumab, Acalabrutinib and Venetoclax
(1084129)
Moritz Fürstenau, MD
11:20 AM (EDT)
17:20 (CEST)
10 mins **MRD dynamics of patients receiving ibrutinib plus venetoclax in the Blood Cancer UK TAP CLARITY study
(1084344)
Talha Munir, MBBS, MRCP, FRCPath
11:30 AM (EDT)
17:30 (CEST)
5 mins Visit Exhibit Hall & Break  
11:35 AM (EDT)
17:35 (CEST)
60 mins Industry Supported Symposia  
12:35 PM (EDT)
18:35 (CEST)
10 mins Binet/Rai Medal Presentation
 
12:45 PM (EDT)
18:45 (CEST)
5 mins Session 6: Front-Line Therapy of CLL

Co-Chairs: Barbara Eichhorst, MD
& Lydia Scarfo, MD
    Relevant Factors for Choice of Frontline Therapy
On-Demand Presentation

Arnon Kater, MD, PhD
    Treatment of Very High Risk CLL
(TP53, Complex Karyotype; IGHV Subset 2)
On-Demand Presentation

Inhye Ahn, MD
    Chemotherapy in the Front Line Setting: Is it Still Useful in Combination with Newer Substances?
On-Demand Presentation

Matthew Davids, MD, MMSc
12:50 PM (EDT)
18:50 (CEST)
30 mins Panel Discussion featuring highlights from the following on-demand presentations:
*Relevant Factors for Choice of Frontline Therapy
*Treatment of Very High Risk CLL (TP53, Complex Karyotype; IGHV Subset 2)
*Chemotherapy in the Front Line Setting: Is it Still Useful in Combination with Newer Substances?
Barbara Eichhorst, MD; Lydia Scarfo, MD; Arnon Kater, MD, PhD; Inhye Ahn, MD; Matthew Davids, MD, MMSc
1:20 PM (EDT)
19:20 (CEST)
10 mins **Fixed-duration (FD) first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma: primary analysis of the FD Cohort of the Phase 2 CAPTIVATE Study
(1084132)
William G. Wierda, MD, PhD
1:30 PM (EDT)
19:30 (CEST)
10 mins **Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study
(1083667)
Wojciech Jurczak, MD, PhD
1:40 PM (EDT)
19:40 (CEST)
  End of Day 2  
1:40 PM (EDT)
19:40 (CEST)
60 mins Poster Session

 
1:40 PM (EDT)
19:40 (CEST)
  Venetoclax Ramp-Up Strategies For CLL. UK Real World Multicentre Retrospective Study
(1084425)
Rocío Figueroa
1:45 PM (EDT)
19:45 (CEST)
  Ibrutinib Followed by Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial from the Spanish Group of CLL (GELLC)
(1083359)
Pau Abrisqueta, MD
1:50 PM (EDT)
19:50 (CEST)
  Preliminary Results of the FILO Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) versus FCR
(1084072)
Anne-Sophie Michallet
1:55 PM (EDT)
19:55 (CEST)
  Utilizing serial Minimal Residual Disease (MRD) assessments:
Long-term outcomes and insights from modeling MRD growth by Next-Generation Sequencing (NGS) within the randomized CLL14 study evaluating fixed-duration therapy with venetoclax and obinutuzumab
(1083240)
Othman Al-Sawaf, MD
2:00 PM (EDT)
20:00 (CEST)
  The Impact of COVID-19 on UK CLL Patients
(1084086)
Renata Walewska, MB ChB PhD
2:05 PM (EDT)
20:05 (CEST)
  Mono-therapy of ibrutinib effectively reduced the incidence of Richter transformation in secondary but not primary lymphoid organs and failed in treating transformed lymphoma in pre-clinical mouse models
(1084604)
Shih-Shih Chen, PhD
2:10 PM (EDT)
20:10 (CEST)
  Outcomes beyond progression in ibrutinib-treated patients with chronic lymphocytic leukemia
(1084582)
Paul J. Hampel, MD
2:15PM (EDT)
20:15 (CEST)
  Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Sequentially Resistant to Both BCL2 and BTK Inhibition
(1083790)
Victor S. Lin, MD
2:20 PM (EDT)
20:20 (CEST)
  Discussion  
2:40 PM (EDT)
20:40 (CEST)
  Poster Session Concludes  

Sunday 19 September 2021

Day 3
7:45 AM (EDT)
13:45 (CEST)
60 mins Industry Supported Symposium  
9:00 AM (EDT)
15:00 (CEST)
5 mins Opening Remarks & Recap of Previous Day

Jan Burger, MD, PhD

9:05 AM (EDT)
15:05 (CEST)
5 mins Session 7: Treatment of Relapsed/Refractory CLL

Co-Chairs: John Seymour, MD
& Meghan Thompson, MD
    Resistance to Venetoclax: Mechanisms, Risk Factors
and Preventative Strategies
On-Demand Presentation

Andrew Roberts, MBBS, PhD
    A Clinical Perspective on Resistance to Covalent BTKi
On-Demand Presentation

Jennifer Woyach, MD
    Using Genomics and Biologic Profiling to Select the
Preferred Targeted Agent for Each Patient
On-Demand Presentation

Richard Rosenquist, MD, PhD
9:10 AM (EDT)
15:10 (CEST)
30 mins Panel Discussion featuring highlights from
the following on-demand presentations:
*Resistance to Venetoclax: Mechanisms, Risk Factors,
and Preventative Strategies
*A Clinical Perspective on Resistance to Covalent BTKi
*Using Genomics and Biologic Profiling to Select the Preferred
Targeted Agent for Each Patient
John Seymour, MD; Meghan Thompson, MD; Andrew Roberts, MBBS, PhD;
Jennifer Woyach, MD; Richard Rosenquist, MD, PhD
9:40 AM (EDT)
15:40 (CEST)
10 mins **Efficacy and Safety of Acalabrutinib versus Ibrutinib in Previously
Treated Chronic Lymphocytic Leukemia: Results of a Phase 3 Clinical Trial
(1083838)
Peter Hillmen, MB ChB, PhD
9:50 AM (EDT)
15:50 (CEST)
10 mins **First Interim Analysis of ALPINE Study: Results of a Phase 3
Randomized Study of Zanubrutinib vs Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small
Lymphocytic Lymphoma
(1084141)
Peter Hillmen, MB ChB, PhD
10:00AM (EDT)
16:00 (CEST)
5 mins Visit Exhibit Hall & Break  
    Theme 3: Rationally Designed Therapy on the Horizon in CLL  
10:05 AM (EDT)
16:05 (CEST)
5 mins Session 8: New Agents in CLL Clinical Trials

Co-Chairs: Jennifer Woyach, MD
& Lindsey Roeker, MD
    Refining our Standard Approaches
On-Demand Presentation

Paolo Ghia, MD, PhD
    Reversible BTK Inhibitors
On-Demand Presentation

Jennifer Brown, MD, PhD
    Preclinical Methods for Drug Discovery
On-Demand Presentation

Rosa Lapalombella, PhD
10:10 AM (EDT)
16:10 (CEST)
30 mins Panel Discussion featuring highlights from the following
on-demand presentations:
*Refining our Standard Approaches
*Reversible BTK Inhibitors
*Preclinical Methods for Drug Discovery
Jennifer Woyach, MD; Lindsey Roeker, MD; Paolo Ghia, MD, PhD; Jennifer Brown, MD, PhD; Rosa Lapalombella, PhD
10:40 AM (EDT)
16:40 (CEST)
10 mins **Pirtobrutinib (LOXO-305), a Next Generation, Highly Selective,
Non-covalent BTK Inhibitor in Previously Treated CLL/SLL:
Results from the Phase 1/2 BRUIN Study
(1084067)
Wojciech Jurczak, MD, PhD
10:50 AM (EDT)
16:50 (CEST)
10 mins **A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax
in Patients with Relapsed or Refractory Chronic
Lymphocytic Leukemia (CLL)
(1083987)
Paul M. M. Barr, MD
11:00 AM (EDT)
17:00 (CEST)
60 mins Industry Supported Symposia

 
12:00 AM (EDT)
18:00 (CEST)
5 mins Visit Exhibit Hall & Break  
12:05 PM (EDT)
18:05 (CEST)
5 mins Session 9: Immunotherapy of CLL

Co-Chairs: John Gribben, MD, DSc
& David Maloney, MD, PhD
12:10 PM (EDT)
18:10 (CEST)
30 mins Debate – CAR T-cell Therapy vs Allo-SCT

Moderators: John Gribben, MD, DSc;

Debaters:
Jordan Gauthier MD, MSc; Peter Dreger, MD

    T Cells in CLL Biology and Treatment: Friends or Foe?
On-Demand Presentation

Jan Burger, MD, PhD
    Bispecific Monoclonal Antibodies
On-Demand Presentation

Adrian Wiestner, MD, PhD
12:40 PM (EDT)
18:40 (CEST)
12 mins **TRANSCEND CLL 004: Phase 1 Cohort of Lisocabtagene
Maraleucel (Liso-cel) Combined with Ibrutinib for Patients with Relapsed/Refractory CLL/SLL
(1084088)
William G. Wierda, MD, PhD
12:52 PM (EDT)
18:52 (CEST)
12 mins **CD19 promoter hypermethylation as means of antigen-negative
escape to CART-19 therapy
(1084273)
Lenka Dostalova
1:05 PM (EDT)
19:05 (CEST)
25 mins Panel Discussion featuring the following on-demand presentations:
*Bispecific Monoclonal Antibodies
*T Cells in CLL Biology and Treatment: Friends or Foe?
John Gribben, MD, DSc
David Maloney, MD, PhD
Jan Burger, MD, PhD
Adrian Wiestner, MD, PhD
Jordan Gauthier MD, MSc
Peter Dreger, MD
1:30 PM (EDT)
19:30 (CEST)
  End of Day 3  
1:30 PM (EDT)
19:30 (CEST)
60 mins Poster Session

 
1:30 PM (EDT)
19:30 (CEST)
  Longer term follow-up of a multicenter, phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, rituximab (iFCR) as initial therapy
for younger patients with chronic lymphocytic leukemia
(1084315)
Matthew S. Davids, MD, MMSc
1:35 PM (EDT)
19:35 (CEST)
  A Phase I Trial of Nedd8-Activating Enzyme (NAE)
Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in
Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic
Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
(1082565)
Pallawi Torka, MD
1:40 PM (EDT)
19:40 (CEST)
  Chronic lymphocytic leukemia actively induces T-cell dysfunction
by contact-dependent signaling
(1084598)
J.A.C. van Bruggen
1:45 PM (EDT)
19:45 (CEST)
  Pirtobrutinib (LOXO-305), A Next Generation, Highly Selective,
Non-covalent BTK Inhibitor in Previously Treated CLL/SLL:
Results from the Phase 1/2 BRUIN Study
(1084540)
Wojciech Jurczak, MD, PhD
1:50 PM (EDT)
19:50 (CEST)
  BTK inhibitors, irrespective of ITK inhibition, downregulate an
immunosuppressive program in chronic lymphocytic leukemia
and enhance CD19/CD3-mediated cytotoxicity of T cells (1084197)
Maissa Mhibik, PhD
1:55 PM (EDT)
19:55 (CEST)
  First-in-human Study of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor,
in Patients with Relapsed/refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Other Hematologic Malignancies (HMs)
(1082531)
Sikander Ailawadhi, MD
2:00 PM (EDT)
20:00 (CEST)
  G-1701, a Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients
with Chronic Lymphocytic Leukemia
(1083634)
Chan Y. Cheah, MBBS, DMSc
2:05 PM (EDT)
20:05 (CEST)
  Dual Variable Domain Antibodies Against FcμR for Potential Treatment of Chronic Lymphocytic Leukemia
(1083985)
Amro A. Fulfulan, MS
2:10 PM (EDT)
20:10 (CEST)
  Discussion  
2:30 PM (EDT)
20:30 (CEST)
  Poster Session Concludes  

Monday 20 September 2021

Day 4
9:00 AM (EDT)
15:00 (CEST)
5 mins Opening Remarks & Recap of Previous Day

Tamar Tadmor, MD

9:05 AM (EDT)
15:05 (CEST)
5 mins Session 10: Supportive Care and Consequences
of
Immune Dysregulation in CLL

Co-Chairs: Jennifer Brown, MD, PhD; & Jackie Barrientos, MD
    Infection Risk in CLL
On-Demand Presentation

Carsten Niemann, MD, PhD
    Infection Risk with Novel Agents
On-Demand Presentation

Florence Cymbalista, MD, PhD
    COVID-19 and CLL
On-Demand Presentation

Lydia Scarfò, MD
    Management of Autoimmune Cytopenias in
the Era of Targeted Agents
On-Demand Presentation

Kerry Rogers, MD
    Management of Cardiac Complications
of BTK Inhibitors
On-Demand Presentation

Javid Moslehi, MD
9:10 AM (EDT)
15:05 (CEST)
5 mins ** Longitudinal antibody Levels and T- cell Response Following BNT162b mRNA Covid19 Vaccine in Patients with Chronic Lymphocytic Leukemia. on Behalf of the Israeli CLL Study Group
(1083588)
Tamar Tadmor, MD
9:15 AM (EDT)
15:15 (CEST)
5 mins **Humoral response to mRNA vaccines BNT162b2 and
mRNA-1273 COVID-19 in chronic lymphocytic leukemia patients
(1084475)
Cristina Bagacean, MD, PhD
9:20 AM (EDT)
15:20 (CEST)
35 mins Panel Discussion featuring the
following on-demand presentations:
*Infection Risk in CLL
*Infection Risk with Novel Agents
*COVID-19 and CLL
*Management of Autoimmune Cytopenias in the Era of Targeted Agents
*Management of Cardiac Complications of BTK Inhibitors
Jennifer Brown, MD, PhD; Jackie Barrientos, MD; Carsten Niemann, MD, PhD; Florence Cymbalista, MD, PhD; Kerry Rogers, MD; Lydia Scarfò, MD; Javid Moslehi, MD
9:55 AM (EDT)
15:55 (CEST)
60 mins Industry Supported Symposia  
10:55 AM (EDT)
16:55 (CEST)
5 mins Visit Exhibit Hall & Break  
    Theme 4: From Global Perspectives to Patient Experiences
– How iwCLL Is Leading the Way
 
11:00 AM (EDT)
17:00 (CEST)
5 mins Session 11: Real-World Data and Patient Experiences

Co-chairs: Peter Hillmen, MB ChB, PhD; John Seymour, MD
11:05 AM (EDT)
17:10 (CEST)
10 mins The iwCLL Global Partnerships Sub-Committee Update
Anna Schuh, MD, PhD
11:15 AM (EDT)
17:15 (CEST)
7 mins ERIC Updates
Paolo Ghia, MD, PhD
11:22 AM (EDT)
17:22 (CEST)
7 mins Update on Geographic Diversity and Management of CLL in China
Shenmiao Yang, MD
11:29 AM (EDT)
17:29 (CEST)
7 mins Update on Geographic Diversity and Management of CLL in South America
Carlos Sergio Chiattone, MD, MSc, PhD
11:36 AM (EDT)
17:36 (CEST)
7 mins Update on Geographic Diversity
and Management of CLL in Africa
Clara Chamba, MD
11:43 AM (EDT)
17:43 (CEST)
5 mins **Comparison of Clinical and Laboratory Features, Drug Availability,
and Outcomes of CLL Patients Treated in Public or in Private
Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL
(1083568)
Verena Pfister
11:48 AM (EDT)
17:48 (CEST)
5 mins **Differences in Availability of Targeted Inhibitors and Use of Chemoimmunotherapy in the First – Line Therapy of Chronic
Lymphocytic Leukemia. a European Survey
(1083141)
Lukáš Smolej, MD, PhD
11:53 AM (EDT)
17:53 (CEST)
15 mins Real-World Data Roundtable Discussion
Peter Hillmen, MB ChB, PhD
Anna Schuh, MD
Paolo Ghia, MD, PhD
Shenmiao Yang, MD
Carlos Sergio Chiattone, MD, MSc, PhD
Clara Chamba, MD
12:08 PM (EDT)
18:08 (CEST)
7 mins Visit Exhibit Hall & Break  
12:15 PM (EDT)
18:15 (CEST)
  Session 11: Real-World Data and Patient
Experiences (Part 2)
 
12:15 PM (EDT)
18:15 (CEST)
45 mins Live Panel Discussion:
Spotlight on the CLL Patient Experience: Perspectives Learned
From Three Datasets & Patient Experience/Perspective/Solutions
John Seymour, MD; Deborah Sims; Dr. Brian Koffman, CMO and EVP, CLL Society; Lorna Warwick, CEO, Lymphoma Coalition; Zack Pemberton-Whiteley, CEO, Leukaemia Care
1:00 PM (EDT)
19:00 (CEST)
5 mins Session 12: Looking to the Future of CLL and iwCLL Michael Hallek, MD, PhD; Peter Hillmen, MB ChB, PhD
1:05 PM (EDT)
19:05 (CEST)
30 mins Keynote: Advances in CLL: Is It Time to Talk Cure?
Michael Hallek, MD, PhD
1:35 PM (EDT)
19:35 (CEST)
15 mins iwCLL Updates and iwCLL 2023
Peter Hillmen, MB ChB, PhD; Jennifer Brown, MD, PhD
1:50 PM (EDT)
19:50 (CEST)
5 mins Closing Comments
Michael Hallek, MD, PhD
1:55 PM (EDT)
19:55 (CEST)
  Close of Workshop